Medpace (NASDAQ:MEDP) Stock Price Down 0.5%

Medpace Holdings, Inc. (NASDAQ:MEDP)’s share price fell 0.5% during trading on Wednesday . The stock traded as low as $398.00 and last traded at $400.10. 34,202 shares were traded during trading, a decline of 86% from the average session volume of 246,387 shares. The stock had previously closed at $402.10.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on MEDP shares. Robert W. Baird upped their price target on Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and upped their target price for the stock from $340.00 to $450.00 in a report on Tuesday, April 23rd. Guggenheim boosted their price target on shares of Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Medpace in a research note on Monday, March 18th. They set a “hold” rating and a $395.00 price objective on the stock. Finally, UBS Group upgraded shares of Medpace from a “neutral” rating to a “buy” rating and lifted their target price for the company from $282.00 to $452.00 in a research note on Thursday, February 15th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $443.00.

Medpace Stock Performance

The stock has a market cap of $12.01 billion, a price-to-earnings ratio of 39.64, a PEG ratio of 1.95 and a beta of 1.40. The firm’s 50-day simple moving average is $398.00 and its two-hundred day simple moving average is $334.20.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, beating analysts’ consensus estimates of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The business had revenue of $511.00 million during the quarter, compared to analyst estimates of $512.39 million. During the same quarter last year, the business posted $2.27 earnings per share. Medpace’s revenue for the quarter was up 17.7% compared to the same quarter last year. Equities research analysts expect that Medpace Holdings, Inc. will post 11.23 earnings per share for the current fiscal year.

Insider Transactions at Medpace

In other news, CEO August J. Troendle sold 15,102 shares of the firm’s stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $400.69, for a total value of $6,051,220.38. Following the transaction, the chief executive officer now owns 791,541 shares of the company’s stock, valued at approximately $317,162,563.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO August J. Troendle sold 15,102 shares of the stock in a transaction on Monday, April 29th. The stock was sold at an average price of $400.69, for a total value of $6,051,220.38. Following the transaction, the chief executive officer now owns 791,541 shares of the company’s stock, valued at approximately $317,162,563.29. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO August J. Troendle sold 100,000 shares of the company’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total value of $41,298,000.00. Following the completion of the sale, the chief executive officer now owns 4,833,019 shares of the company’s stock, valued at approximately $1,995,940,186.62. The disclosure for this sale can be found here. Insiders sold a total of 204,442 shares of company stock worth $82,702,867 over the last 90 days. 20.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of MEDP. ProShare Advisors LLC boosted its position in shares of Medpace by 3.1% during the first quarter. ProShare Advisors LLC now owns 3,337 shares of the company’s stock worth $1,349,000 after purchasing an additional 101 shares in the last quarter. QRG Capital Management Inc. lifted its holdings in Medpace by 322.5% during the first quarter. QRG Capital Management Inc. now owns 10,553 shares of the company’s stock worth $4,265,000 after acquiring an additional 8,055 shares in the last quarter. Meeder Advisory Services Inc. acquired a new position in Medpace in the first quarter valued at about $230,000. Sei Investments Co. increased its holdings in shares of Medpace by 12.7% in the first quarter. Sei Investments Co. now owns 135,649 shares of the company’s stock worth $54,822,000 after acquiring an additional 15,304 shares in the last quarter. Finally, GW Henssler & Associates Ltd. acquired a new stake in shares of Medpace during the first quarter worth about $224,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.